title: [Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA].
authors.forename: Thomas
authors.initials: T
authors.lastname: Berg
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Michael P
authors.initials: MP
authors.lastname: Manns
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects* / Q000592:standards; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000592:standards; D019317:Evidence-Based Medicine; D005449:Fluorenes / Q000008:administration & dosage* / Q000009:adverse effects* / Q000592:standards; D005762:Gastroenterology / Q000592:standards*; D005858:Germany; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D000069474:Sofosbuvir; D016896:Treatment Outcome; D014542:Uridine Monophosphate / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000592:standards
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; C000595958:ledipasvir, sofosbuvir drug combination; D014542:Uridine Monophosphate; D000069474:Sofosbuvir